Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study.
Quick Facts
What This Study Found
In over 214,000 matched patients with type 2 diabetes, GLP-1 receptor agonist users had 19% lower risk of new neurodegenerative disease compared to DPP-4 inhibitor users over 4 years. The association held for dementia and Alzheimer's but not Parkinson's disease.
Key Numbers
214,442 matched individuals. Mean follow-up 4.0 years. Composite neurodegeneration HR 0.81 (95% CI 0.77-0.86). Dementia HR 0.76. Alzheimer's HR 0.77. Vascular dementia HR 0.75. Parkinson's HR 1.04 (not significant). Semaglutide HR 0.75, liraglutide HR 0.77, dulaglutide HR 0.82.
How They Did This
Retrospective cohort using TriNetX platform (170M+ records). Propensity-score matched 1:1. GLP-1RA vs DPP-4i initiators (2010-2021). Cox regression for composite and individual neurodegenerative outcomes over up to 5 years. Separate analysis vs basal insulin.
Why This Research Matters
Type 2 diabetes significantly increases dementia risk. This large real-world study adds to growing evidence that GLP-1 drugs may protect the brain, supporting the case for dedicated clinical trials.
What This Study Doesn't Tell Us
Observational design cannot prove causation. Potential residual confounding despite matching. Database study may have diagnostic coding inaccuracies. Parkinson's showed no benefit.
Trust & Context
- Original Title:
- Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study.
- Published In:
- Cardiovascular diabetology, 24(1), 426 (2025)
- Authors:
- Schechter, Meir, Fishkin, Alisa, Mosenzon, Ofri(4), Sehtman-Shachar, Dvora R, Cukierman-Yaffe, Tali, Leibowitz, Gil, Aharon-Hananel, Genya
- Database ID:
- RPEP-13452
Evidence Hierarchy
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13452APA
Schechter, Meir; Fishkin, Alisa; Mosenzon, Ofri; Sehtman-Shachar, Dvora R; Cukierman-Yaffe, Tali; Leibowitz, Gil; Aharon-Hananel, Genya. (2025). Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study.. Cardiovascular diabetology, 24(1), 426. https://doi.org/10.1186/s12933-025-02962-8
MLA
Schechter, Meir, et al. "Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study.." Cardiovascular diabetology, 2025. https://doi.org/10.1186/s12933-025-02962-8
RethinkPeptides
RethinkPeptides Research Database. "Neurodegeneration onset with glucagon-like peptide-1 recepto..." RPEP-13452. Retrieved from https://rethinkpeptides.com/research/schechter-2025-neurodegeneration-onset-with-glucagonlike
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.